The trade show floor offers a firsthand look at how market trends shape current design and manufacturing innovations.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...

Sliding scale insulin therapy involves following a chart of insulin dosages. A doctor will help a person with diabetes create this chart based on factors like how their body responds to insulin ...

Insulin-like growth factor (IGF) 1 is a member of a family that is involved in growth, development, cell differentiation, and metabolism. IGF1, IGF2 and insulin act primarily through tyrosine ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

ST. PAUL, Minn. — Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable ...

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at ...